<DOC>
	<DOCNO>NCT01871311</DOCNO>
	<brief_summary>The purpose study determine recommend Phase II dose nilotinib use combination cetuximab treatment patient recurrent and/or metastatic Kras wildtype colorectal cancer squamous cell carcinoma head neck .</brief_summary>
	<brief_title>A Phase I Study Nilontinib Cetuximab Patients With Solid Tumors</brief_title>
	<detailed_description>ABL1 suggest play key role resistance mechanism anti EGFR therapy cancer . Therefore , study aim evaluate safety possible effect target EGFR use cetuximab along ABL1 use nilotinib . Correlative study assess change tumor proteome response therapy magnitude ADCC marker antibody activity .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Recurrent and/or metastatic Kras wildtype colorectal cancer squamous cell carcinoma head neck 2 . Previous therapy : 1 . Patients must progress standard therapy metastatic/recurrent disease , include irinotecan oxaliplatincontaining regimens patient CRC platinumcontaining regimen patient H &amp; NSCC . 2 . Patients may receive cetuximab panitumumab previously 3 . Ability swallow medication tablet mouth ( may include take nilotinib mixed apple sauce ) 4 . At least one measurable lesion RECIST criterion 5 . A tumor lesion readily biopsied use core needle via clinical exam imageguidance . 6 . Over age 18 year able provide inform consent 7 . Adequate kidney , liver , bone marrow function follow : 1 . Hemoglobin &gt; /= 8.0 gm/dL 2 . Absolute neutrophil count &gt; /= 1500 3 . Platelet count &gt; /= 100,000 4 . Creatinine within institutional normal limit glomerular filtration rate &gt; 60 5 . Total bilirubin f. AST ALT 8 . Life expectancy great 3 month 9 . ECOG performance status 10 . Normal leave ventricular ejection fraction , define EF &gt; 50 % 1 . Chemotherapy surgery within 4 week prior treatment start 2 . Radiation treatment within 3 week prior treatment start 3 . Prior therapy nilotinib , ponatinib , dasatinib , imatinib 4 . Untreated brain metastasis neurologically unstable central nervous system metastasis ; CNS metastases consider stable new enlarge lesion one month , patient remain steroids antiepileptic time period 5 . Any severe uncontrolled medical condition condition could affect participation study , include : unstable angina , uncontrolled hypertension , serious uncontrolled cardiac arrhythmia , uncontrolled infection , myocardial infarction 6 . Diarrhea &gt; Grade 1 baseline 7 . Concomitant medication herbal therapy know inhibit CYP3A4 8 . Gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease 9 . Ongoing ventricular cardiac dysrhythmias NCI CTCAE grade &gt; /= 2 10 . Subjects history serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation &gt; /= 3 beat row ) 11 . Serious cardiac arrhythmia require medication 12 . QTc interval &gt; 500 msec 13 . Female patient pregnant breast feeding , adult reproductive potential unwilling refrain conceive child study treatment 14 . Patients unwilling unable comply protocol , provide informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metastatic Kras wildtype</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>cetuximab</keyword>
	<keyword>nilotinib</keyword>
</DOC>